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Abstract: We examined a nonplatinum-based doublet chemotherapy
regimen, pemetrexed and gemcitabine given on a biweekly (every 14
days) schedule, in patients older than 70 years with newly diagnosed
advanced non-small cell lung cancer. The study was closed after nine
patients were treated due to excess toxicity, primarily fatigue, and
nonneutropenic infection. No responses were observed. Eight of the
nine patients were hospitalized during therapy and seven discontinued
treatment for reasons other than progressive disease. Median progres-
sion-free survival was 1.7 months, and median overall survival was 3.9
months. We found that biweekly pemetrexed and gemcitabine was too
toxic in our cohort of elderly patients with newly diagnosed advanced
non-small cell lung cancer.
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The median age at diagnosis with non-small cell lungcancer (NSCLC) is 70 years. Although combination che-
motherapy offers a modest survival benefit in advanced
NSCLC, whether this extends to elderly patients is contro-
versial because underrepresentation in clinical trials limits
evidence-based statements about this cohort. Although single
agent vinorelbine improved survival over supportive care in
an elder-specific randomized trial,1 there is a lack of conclu-
sive data regarding combination chemotherapy in elderly
patients with NSCLC.2
Both pemetrexed (Alimta) and gemcitabine (Gemzar) are
Food and Drug Administration-approved drugs for the treatment
of NSCLC. The combination is rational because both deplete
intracellular stores of deoxynucleotide triphosphates and syn-
ergy is observed in preclinical models. Several phase I and phase
II studies have examined the combination in NSCLC, varying
the sequence and days of administration of the drugs.3–10 The
biweekly (twice a month) regimen allows for a patient-friendly
schedule and had a relatively low rate of neutropenia in phase I
trials. Hence, we explored this nonplatinum-based combination
as first-line therapy for elderly patients.
METHODS
This was a single institution, open-label phase II study
to assess the objective response rate and safety of first-line
biweekly gemcitabine and pemetrexed in patients older than
70 years with advanced NSCLC (any histology). Key inclu-
sion criteria included performance status (PS) of 0 to 2,
measurable disease, and prior definitive treatment of central
nervous system metastases. The planned sample size was 55
patients, with interim analysis and stopping for lack of activ-
ity. Enrollment began on August 3, 2005. After seven patients
were treated, clinical concern was raised that toxicity was
higher than expected. The starting dose of both drugs was
reduced; however, after two patients were treated at the lower
doses without an improvement in safety, the study was closed
on December 5, 2006.
Treatment was in 2-week cycles; the dose for the first
seven patients was pemetrexed 500 mg/m2 followed by gem-
citabine 1500 mg/m2 on day 1 of each cycle, and the final two
patients received pemetrexed 400 mg/m2 and gemcitabine
1000 mg/m2. All patients received vitamin B12, folic acid,
and dexamethasone as recommended with pemetrexed. Treat-
ment continued until disease progression or unacceptable toxic-
ity. Adverse events were graded by the NCI-CTCAE, version
3.0. Response was evaluated every 8 weeks (4 cycles). The
clinical trial protocol was approved and monitored by our
institutional review board. Funding was provided by Eli Lilly
and Company.
RESULTS
Nine patients were enrolled, aged 70 to 82 years,
including three women, six with adenocarcinoma, three with
poorly differentiated carcinoma, one with central nervous
system metastases, and with baseline PS of 0 (n  2), 1 (n 
6), or 2 (n  1). Chemotherapy cycles administered ranged
from 1 to 5; four patients received only 1 cycle because of
adverse events. Indeed, toxicity was the limiting factor in
treatment length for most patients, Table 1. Eight of the nine
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patients were hospitalized during therapy, and only two
patients discontinued protocol therapy for documented dis-
ease progression, while the remaining seven discontinued for
intolerance and declining PS.
Table 2 summarizes all observed adverse events. Six of
the nine patients had at least one grade 3 or greater treatment-
related toxicity. Fatigue occurred in all patients. Nonneutro-
penic infections were noted in five patients, specifically
pneumonia in three subjects and one each of urosepsis and
cellulitis. Two patients died within 30 days of cycle 1; one
from hemoptysis and one from respiratory failure related to
pneumonia and underlying disease. Other significant treat-
ment-related adverse events included anorexia, constipation,
neutropenia, and pneumonitis.
There were no objective tumor responses by RECIST.
One patient achieved a minor clinical response (patient 8),
followed by 4 months of stable disease off therapy. The upper
limit of the one-sided 95% confidence interval (CI) for the
response rate of 0% was 28%. Power is extremely limited for
survival analysis; the observed median progression-free sur-
vival was 1.7 months, 95% CI 1.5 to 2.5 months, and the
median overall survival was 3.9 months, 95% CI 1.6 to 14.3
months.
DISCUSSION
We have demonstrated that the first-line biweekly pem-
etrexed and gemcitabine was poorly tolerated in a cohort of
nine patients older than 70 years with advanced NSCLC.
There were unacceptable levels of fatigue and infection, even
in the absence of neutropenia. We had designed this phase II
clinical trial to assess the response rate to biweekly pem-
etrexed and gemcitabine among elderly patients, but the study
was closed early for intolerance. No responses were noted in
the small number of patients participating, and the progres-
sion-free survival and overall survival were unusually low,
TABLE 1. Treatment-Related Major Events
Patient Age (yr) PS No. of Cycles Major Events Experienced by Patient
1 70 0 1 C1: admitted with G4 pneumonia (nonneutropenic). Complicated hospital course with atrial fibrillation and
hypoxia, died of respiratory failure 14 d after C1.
2 75 1 5 C4: admitted for pleurodesis with increasing pleural effusion, tumor mass stable so treatment continued.
C5: admitted with failure to thrive including G4 fatigue, G3 dyspnea; discharged home with hospice care and
lived approximately 2 mo.
3 79 1 3 C2: admitted with G3 pneumonia (nonneutropenic). Progressive disease after C3 went on to receive multiple
subsequent regimens.
4 73 0 5 C3: admitted with G1 cellulitis (nonneutropenic). Withdrew consent after C5 for ongoing G2 fatigue and
declining PS, required inpatient nursing home care from that time until death 6 wk later.
5 72 1 3 Tolerated treatment well, but progression after C3, went on to receive one subsequent regimen.
6 70 1 1 C1: admitted with G3 pneumonia (nonneutropenic) and G3 fatigue, discharged home with hospice care, and
lived 1 mo.
7 76 1 1 C1: admitted with G3 urospesis (nonneutropenic) and G2 hypotension requiring a brief course of pressors.
Withdrew consent and went on to receive multiple subsequent regimens.
8 71 1 4 C4: admitted with G4 pulmonary embolism, G3 neutropenia and G2 fatigue, dehydration, and diarrhea.
Discharged home with hospice care and lived at least 7 more months until lost to follow-up.
9 82 2 1 C1: admitted with G2 fatigue and dizziness resulting in a fall with head laceration, complicated by new onset
atrial fibrillation (not anticoagulated). Fatal hemoptysis at home 14 d after C1 with platelets  166 earlier
that day.
PS, performance status at the time of enrollment; No. of cycles, total number of treatment cycles received; C, cycle number; G, grade of toxicity.
TABLE 2. Adverse Events
Toxicity
Toxicity Grades, n (%)
1 2 3 4 5
Likely treatment related
Fatigue 3 (33) 4 (44) 1 (11) 1 (11) —
Infection or fever
without neutropenia
1 (11) — 3 (33) 1 (11) —
Anorexia 3 (33) 3 (33) — — —
Constipation — 5 (56) — — —
Insomnia 3 (33) — — — —
Neutropenia — 1 (11) 1 (11) — —
Dehydration — 2 (22) — — —
Weakness — 2 (22) — — —
Dizziness/hypotension — 2 (22) — — —
Nausea/vomiting 2 (22) — — — —
Pneumonitis — — — 1 (11) —
Anemia — 1 (11) — — —
Myalgias — 1 (11) — — —
Diarrhea 1 (11) — — — —
Transaminitis 1 (11) — — — —
Phlebitis 1 (11) — — — —
Anxiety 1 (11) — — — —
Likely disease related
Cough 4 (44) 3 (33) — — —
Dyspnea/resp. failure — 3 (33) 1 (11) — 2 (22)
Bleeding/hemoptysis 1 (11) — 2 (22) — 1 (11)
Pain 1 (11) 2 (22) 1 (11) — —
Hypoxia — — — 2 (22) —
Pulmonary embolism — — — 1 (11) —
Atrial fibrillation — 1 (11) — — —
Confusion 1 (11) — — — —
n, number; resp., respiratory.
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1.7 months and 3.9 months, respectively, likely influenced by
two deaths during the first cycle of therapy.
The adverse events we observed tended to be multiple
grade 1/2 toxicities per patient, as opposed to a primary grade
3/4 adverse event; this led to a significant proportion of the
patients (seven of nine) electing to withdraw from protocol
treatment before documented disease progression. In elderly
patients, this is a clinically significant finding, as multiple
low-grade toxicities can lead to loss of independence and
decreased quality of life. Indeed, seven of our patients were
hospitalized during protocol treatment, and five of these
either died in the hospital that admission or were dis-
charged to hospice or permanent nursing home placement.
Undocumented disease progression may also have contrib-
uted to clinical decline in some of these patients, particu-
larly the three that died within 2 months of elective
withdrawal from protocol.
Biweekly pemetrexed and gemcitabine with the doses
we used initially (500 mg/m2 pemetrexed and 1500 mg/m2
gemcitabine) has been studied as first-line therapy in patients
with NSCLC in three other phase II trials.4–6 All had similar
entry criteria to ours; two were performed in the general
population and the third in either elderly (age of 65 years)
or PS 2 patients. In total, the 169 patients in these studies did
moderately well, with response rates around 20% and grade
3/4 neutropenia in 25 to 45% of patients. The elderly and
poor PS study did not observe increased toxicity among
elderly patients but found the regimen not well tolerated by
poor PS patients.5 Twenty-one-day cycle dosing of pem-
etrexed (500 mg/m2) and gemcitabine (1250 mg/m2 days 1
and 8) has also been studied in four phase II trials comprising
319 patients with response rates ranging from 13 to 31% and
grade 3/4 neutropenia in 40 to 66% of patients, higher than
with the biweekly schedule.7–10 Among all seven other trials,
our study seemed particularly difficult to complete with
acceptable tolerance. It is difficult to interpret the precise
reason for this. Perhaps our patients, although assessed as
having good PS of primarily 0 or 1, were more frail than
appreciated on this subjective scale. Perhaps, it was just
chance that the first cohort of patients we enrolled experi-
enced excess toxicity, or perhaps this regimen truly is too
challenging for elderly patients and the other studies failed to
highlight this fact given the generally younger population of
patients they enrolled. In any case, our results emphasize the
need to exercise caution going forward using the combination
of pemetrexed and gemcitabine in patients with NSCLC older
than 70 years.
The majority of the evidence guiding therapy for older
patients with advanced NSCLC comes from subgroup anal-
yses of elderly patients fit enough to enroll on age-blind
randomized clinical trials.2,11 Although these have generally
concluded that good PS patients older than 70 years can tolerate
platinum-based doublets, ambiguity remains about how to ac-
curately assess fitness level and about the newest regimens for
NSCLC incorporating bevacizumab.12 Robust phase III elder-
specific clinical trials, which tend to best represent “commu-
nity” elderly patients, are few in number but have shown that
single agent vinorelbine improves survival and quality of life
compared with best supportive care and treatment with non-
platinum-containing doublets increases toxicity compared
with single agent therapy without improving efficacy.1,13 One
smaller randomized trial concluded that nonplatinum combi-
nation regimens may increase survival, when compared with
single agents, but it was underpowered to demonstrate this
conclusively.14 Hence, the standard of care for elderly patients
unable to tolerate platinum doublets remains single agent che-
motherapy.2 Further investigation of nonplatinum doublets is of
interest to define a “middle ground” option between mono-
therapy and platinum doublets, but enthusiasm about pem-
etrexed with gemcitabine may be limited by the recent finding
that these drugs may have preferential activity in differing
histologic subgroups.15
In conclusion, we attempted to treat advanced patients
with NSCLC aged 70 years and older with a biweekly regimen
of pemetrexed and gemcitabine. We found that the regimen was
prohibitively difficult to tolerate and closed the study after only
nine patients were treated, instead of the planned 55 subjects.
Our patients experienced multiple grade 1 and grade 2 tox-
icities, including universal fatigue, which contributed to an
unacceptably high rate of hospitalization and loss of indepen-
dence. This regimen should be considered with caution in
elderly patients.
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